Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 203, Issue 8, Pages 1859-1865Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20052136
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA106802, R01 CA109465, CA106802, CA109465] Funding Source: Medline
- NCRR NIH HHS [M01-RR00102, M01 RR000102] Funding Source: Medline
Ask authors/readers for more resources
Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R. M. Steinman. 1998. Nature. 392: 245-252). In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions. Together, these data suggest that tumor-DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available